- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
Closing the gap between basic and clinical CLL research
Emili Montserrat, MD from the Hospital Clinic of Barcelona, Barcelona, Spain discusses his personal highlights from the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. He covers how interest in chronic lymphocytic leukemia (CLL) has expanded enormously, with significant developments. However he also emphasises the importance of closing the gap between basic and clinical science, with more needing to be done in translational research.
Видео Closing the gap between basic and clinical CLL research канала VJHemOnc – Video Journal of Hematology & HemOnc
Видео Closing the gap between basic and clinical CLL research канала VJHemOnc – Video Journal of Hematology & HemOnc
Комментарии отсутствуют
Информация о видео
12 июля 2017 г. 18:27:16
00:03:37
Другие видео канала
Insights into the potential for a cure in myeloma: MRD negativity & CAR-T therapies
How may the subcutaneous OBI version of isatuximab impact the QoL of patients with MM?
Updated results of the Phase III PERSEUS trial evaluating dara-VRd in newly diagnosed myeloma
Frontline and R/R myeloma: an overview of the current treatment landscape
Where do bispecifics and CAR-T stand in the current treatment landscape of Waldenström’s?
Genomic sequencing guides personalized treatment in multiple myeloma
Bispecific antibodies in myeloma: community care considerations & unmet needs
How is the role of sFLC evolving for assessing disease response in myeloma?
REALiTEC cohort 2: teclistamab shows favorable real-world outcomes in R/R myeloma
Recent advances and unmet needs in smoldering multiple myeloma
Expanding access to bispecific antibodies and CAR T-cell therapy in myeloma
Insights into the disease biology & role of T-cell redirecting therapies in EMD
How do tumor subclones and T-cell dynamics influence ibrutinib responses in Waldenström’s?
Single-agent versus combination therapy for maintenance therapy in myeloma
Optimal dosing strategy for BVd in R/R MM: outcomes from the DREAMM-6 arm B trial
Improving risk stratification & early treatment strategies in myeloma and smoldering myeloma
